Upgrades
Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.
The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc’s (NASDAQ:VRCA) marketing application for VP-102 for molluscum contagiosum. The…
Today's 5 Stock Ideas:
NVIDIA (NVDA) - Will report quarterly results Wednesday after market close.
Redbox (RDBX) - One of the most popular stocks among the retail trader group over the last couple weeks.
Martin Shkreli, who infamously raised the price of an antiparasitic drug by 5,455% in 2017, sang praises of Ethereum (CRYPTO: ETH)-based decentralized cryptocurrency exchange Uniswap (UNI) after getting out of prison.
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.